Elixir claim that the device is the first of its kind that releases three types of drugs. Credit: KATERYNA KON/SCIENCE PHOTO LIBRARY via Getty Images.

Elixir Medical’s triple drug-eluting coronary implant has met the primary safety and efficacy endpoints in the DESyne BDS Plus Randomised Controlled Trial (RCT). 

The data was presented at the Transcatheter Cardiovascular Therapeutics (TCT) Annual Scientific Symposium 2023 in San Francisco, US, on 25 October. 

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

DESyne BDS Plus RCT is a prospective, multi-centre, single-blind, randomised Phase II clinical study (NCT05033964) evaluating the safety and efficacy of the DESyne BDS Plus compared to a polymer drug-eluting stent (DES) to treat coronary artery lesions.  

The primary endpoint of the study was successfully met, with a significant difference in the target lesion failure (TLF) rate between the two groups. No cases of probable or definite stent thrombosis, heart attacks related to the treated vessel, or cardiovascular deaths were reported with the device.  

The secondary endpoint, which assessed the late lumen loss within the stented blood vessel, was similar between the two devices. 

See Also:

Elixir claims that DESyne BDS Plus is the world’s first coronary implant that releases three types of drugs. Another significant feature of DESyne BDS Plus is its ability to deliver antithrombotic drugs specifically to the site where the stent is implanted. The targeted approach aims to improve the safety and effectiveness of the device.   

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Elixir has several devices in the pipeline, including its DynamX Coronary Drug-Eluting Bioadaptor, which was tested on 445 patients in the BIOADAPTER RCT trial (NCT04192747), meeting its primary endpoint in May 2023.  

A market model by GlobalData forecasts the drug-eluting stent market to be worth more than $2.3bn in the US by 2030.  

GlobalData is the parent company of Clinical Trials Arena.